To my point cammo, agree totally. With LCT only looking to do procedures @ Ascot for the next year at least (past approval, if gained) there will be plenty of time for the world to come knocking.
70,000 people a year in the US alone are diagnosed with Parkinson's. If LCT has a viable product for the treatment/assistance of Parkinson's then PR will not be an issue.
In the meantime I would rather the company was focussed on a successful trial outcome and being in the position (subject to approval) to begin offering the LCT solution ASAP not only for the financial gain it will deliver to shareholders, but more importantly the prospect of a viable solution to all the people suffering with this terrible condition/ailment.
Ann: Half Yearly Report and Accounts, page-14
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 1AI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.87M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.0¢ | 1.0¢ | $2.099K | 209.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 4988309 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 1307268 | 9 |
View Market Depth
| Last trade - 10.00am 19/06/2024 (20 minute delay) ? |
| 1AI (ASX) Chart |